Uterine Sarcoma: Types & Overview

What Is Uterine Sarcoma?

The womb (uterus) is built in layers. Its inner lining — the endometrium — is the tissue that thickens and sheds each month, and it is the lining that gives rise to endometrial cancer, the common type of uterine cancer most people have heard of. Wrapped around that lining is a thick wall of smooth muscle (the myometrium) and the connective tissue that supports it. Uterine sarcoma — also written as uterus sarcoma or womb sarcoma — is the much rarer cancer that grows out of this muscle and supporting tissue rather than the lining.

That single difference in where the cancer begins explains almost everything about why a sarcoma behaves and is treated differently. Sarcomas are cancers of the body's "scaffolding" tissues — muscle, fat, blood vessels, connective tissue — wherever they occur. Uterine sarcoma is simply a sarcoma that happens to arise inside the womb. It makes up only a small percentage of all cancers of the uterus, but as a group these tumours tend to grow faster, are more likely to spread through the bloodstream (often first to the lungs), and need a treatment plan designed by a team that understands sarcoma, not only routine gynaecologic cancer. You can see how this fits the wider family of these tumours on our sarcoma — overview hub.

One of the reasons uterine sarcoma is so easily missed is that, on a scan or to the touch, an early tumour can look exactly like a fibroid — the extremely common, benign muscle growth that millions of women carry. The vast majority of "lumps in the womb" are harmless fibroids. But a small number of muscle tumours are leiomyosarcomas, and the two are very hard to tell apart before surgery. We explain that crucial distinction in detail on our dedicated uterine leiomyosarcoma vs fibroid page.

The Main Types of Uterine Sarcoma

For anyone researching a diagnosis, the most useful thing to understand is that "uterine sarcoma" is an umbrella term, not a single disease. The histopathology report will name a specific subtype, and that subtype — far more than the word "sarcoma" alone — drives the prognosis and the treatment plan. There are four main types:

You may also see the older term carcinosarcoma (also called malignant mixed Müllerian tumour) mentioned alongside these. Although it was once grouped with uterine sarcomas, modern pathology classifies carcinosarcoma as a type of high-grade endometrial carcinoma that has taken on a sarcoma-like appearance — so it is generally treated along endometrial-cancer lines rather than as a true sarcoma. If your report uses that word, it is worth asking your specialist which pathway applies. To go deeper on the connective-tissue subtype, see our focused page on endometrial stromal sarcoma.

Symptoms and Who It Affects

Uterine sarcoma does not have symptoms unique to it — and that is precisely why it can hide behind common, benign conditions for a while. The signs that should prompt a specialist review include:

• Abnormal vaginal bleeding — heavy or irregular periods, bleeding between periods, or any bleeding after menopause (the single most important red flag).
• A rapidly enlarging "fibroid" — a uterine mass that grows quickly, especially after menopause when fibroids should be shrinking.
• Pelvic pain or pressure — a persistent ache, fullness, or a palpable lower-abdomen mass.
• Unusual vaginal discharge — sometimes watery, foul-smelling, or blood-stained.

Most women with these symptoms do not have a sarcoma — they have fibroids, hormonal changes, or other benign conditions. The point is not to cause alarm but to make sure a rapidly growing mass or post-menopausal bleeding is properly investigated rather than assumed to be harmless. Uterine sarcoma is more common after menopause, and prior pelvic radiation (for an earlier cancer) and long-term tamoxifen are recognised risk factors, but most cases occur in women with none of these.

How Uterine Sarcoma Is Diagnosed and Graded

Because uterine sarcoma so often masquerades as a fibroid, the diagnosis is reached in two quite different ways — sometimes by deliberate investigation, and sometimes only after surgery for a presumed benign mass. Understanding the pathway helps explain why specialist involvement matters from the very start.

Imaging — Ultrasound and MRI

A pelvic ultrasound is usually the first scan, but it cannot reliably tell a sarcoma from a fibroid. MRI is far more informative: it shows the size, location and internal character of the mass, and features such as irregular borders, areas of dead tissue (necrosis) and unusual blood flow can raise suspicion. MRI also maps the tumour's relationship to nearby organs, which is essential for planning surgery. No scan, however, can give a definitive answer on its own — that comes from the tissue.

Tissue Diagnosis — Biopsy and Histopathology

For tumours that involve the womb lining (such as endometrial stromal sarcoma), an endometrial biopsy or hysteroscopic sampling may capture cancer cells. But leiomyosarcomas sit deep within the muscle wall and are notoriously difficult to biopsy reliably before surgery — which is why a significant number are diagnosed only when the removed uterus or "fibroid" is examined under the microscope. The pathologist looks at the cell type, the number of dividing cells (mitoses), the degree of abnormality, and the presence of necrosis to name the exact subtype and assign a grade.

Grade and Stage

Grade describes how aggressive the cells look — low-grade tumours grow slowly and recur late, while high-grade tumours grow and spread quickly. This single factor heavily shapes prognosis and treatment. Stage describes how far the cancer has spread, from confined-to-the-uterus through to distant spread (most often the lungs). The combination of subtype, grade and stage — reviewed together at a tumour board — is what produces an individual treatment plan, rather than a one-size-fits-all protocol.

How Uterine Sarcoma Is Treated

Treatment is built around the subtype, grade and stage — but for almost every patient it begins with surgery, and the goal of that surgery is to remove the tumour intact.

Surgery — Removing the Tumour in One Piece

The mainstay of treatment is a total hysterectomy — removal of the whole uterus with the tumour taken out in one piece (en bloc), without morcellation. In post-menopausal women and for hormone-sensitive tumours, the fallopian tubes and ovaries (a bilateral salpingo-oophorectomy) are usually removed as well. The aim is the same principle that governs sarcoma surgery anywhere in the body: take the tumour out whole, with a clear margin, so cancer cells are not left behind or spread within the pelvis.

Type-Specific Drug and Hormone Therapy

What follows surgery depends heavily on the subtype. High-grade tumours such as uterine leiomyosarcoma and undifferentiated uterine sarcoma often need chemotherapy — the same agents used for other soft tissue sarcomas — either after surgery or for disease that has spread. Low-grade endometrial stromal sarcoma is frequently hormone-driven and responds well to anti-oestrogen (hormone) therapy, which is why removing the ovaries and using hormone-blocking medication is a key part of its management. Radiation therapy may be added for local control in selected cases.

What CION Offers in Hyderabad

At CION, a uterine sarcoma is never managed by a single doctor in isolation. The diagnosis, the histopathology and the imaging are reviewed together at a multidisciplinary tumour board that includes surgical, medical and radiation oncologists, so that surgery is planned to remove the tumour intact and the right type-specific systemic or hormone therapy is chosen. We also provide a free written second opinion — invaluable when a sarcoma has been found unexpectedly after fibroid surgery, or when you simply want to be sure the subtype and plan are correct before treatment begins. Care is delivered across 7 NABH-accredited Hyderabad locations, with insurance, EMI and government scheme support for eligible patients.

Outlook, and How Uterine Sarcoma Differs From Endometrial Cancer

Prognosis in uterine sarcoma varies enormously by subtype, which is why a general "survival rate" for "uterine sarcoma" as a whole is misleading. A low-grade endometrial stromal sarcoma or a low-grade adenosarcoma caught early can have an excellent long-term outlook, often managed successfully with surgery and hormone therapy. A high-grade leiomyosarcoma or undifferentiated sarcoma is more serious and demands more intensive treatment and closer follow-up. The factors that most influence outcome are the same trio reviewed at the tumour board: the exact subtype, the grade, and the stage at diagnosis — together with whether the tumour was removed intact.

Why the Distinction From Endometrial Cancer Matters

It is worth restating the difference clearly, because mixing the two up is the most common confusion patients face. Endometrial carcinoma starts in the womb lining, is by far the most common uterine cancer, usually presents early with post-menopausal bleeding, and tends to have a good prognosis. Uterine sarcoma starts in the muscle or connective tissue, is rare, and as a group is more aggressive and more likely to spread through the bloodstream. They share an organ and some symptoms, but they are biologically different cancers — and being treated by a team that recognises the distinction, and treats sarcoma on sarcoma principles, genuinely changes outcomes.

If you are still piecing together which condition your report describes, two pages will help most: our comparison of uterine leiomyosarcoma vs fibroid for the benign-versus-malignant question, and our focused page on endometrial stromal sarcoma for the connective-tissue subtype. For the full picture of how every sarcoma is staged, treated and followed up, return to the sarcoma — overview hub.

Why Patients Choose CION for Uterine Sarcoma Care

Uterine sarcoma is rare enough that it needs a team who treats it regularly. Here is why patients across Telangana trust CION to get the subtype, the surgery, and the plan right.

Get Clarity on Your Diagnosis

A rare cancer is easier to face when you understand exactly what it is. Talk to a specialist who treats uterine sarcoma regularly — and get a clear, honest plan before any treatment begins.